Max International Acquires CellGevity Technology and Assets
Max International acquired the technology and assets behind CellGevity, a company founded in part by Dr. Herbert Nagasawa after 25 years of scientific research on Glutathione and the benefits it provides the human body. Max International has acquired all of the assets of CellGevity including:
■Patents
■Proprietary Research
■Breakthrough Formulations
■Executive Team
■Research Scientists
What does this mean for Max International?
Max International has long been the leader in glutathione research and this acquisition only further ensures that Max International will remain at the forefront as the undisputed leader in all aspects of the glutathione industry. The science, formulations and patents associated with CellGevity in conjunction with Max International will provide the public with unprecedented glutathione research and products for years to come.
Herbert T. Nagasawa, Ph.D.: Co-Founder, Chairman and Director of Research
Chief Scientist and co-founder of CellGevity, Inc., Dr. Nagasawa received his B.S. degree in chemistry from Western Reserve University (now, Case-Western Reserve) in Cleveland, Ohio, and the Ph.D. degree in organic chemistry from the University of Minnesota. Subsequently, he spent two years as a Post-doctoral Fellow in biochemistry at the University of Minnesota before joining the research staff of the V.A. Medical Center in Minneapolis as a Senior Chemist. He was appointed Assistant Professor of Medicinal Chemistry at the University of Minnesota in 1959. He was named Principal Scientist of the VAMC in 1961 and was promoted in 1976 to Senior Research Career Scientist, a nationwide VA title reserved for the VA’s top scientists. He was promoted to Associate Professor in 1963 and to Professor of Medicinal Chemistry in 1973. He also held joint professorships in the Department of Pharmacology and the university-wide Division of Toxicology, and served as Visiting Professor at Washington State University in 1990. He also served for 32 years as a Senior Editor for the prestigious international Journal of Medicinal Chemistry from 1972 to 2004, and one year as Acting Editor-in-Chief. In addition, he served on the Editorial Board of the journal, Bioconjugate Chemistry for eight years, and as an ad hoc grant reviewer for the NCI and NIAAA, National Institutes of Health. He has published over 165 papers in peer-reviewed journals, and is the inventor named on ten U.S. and PCT patent applications.
Scott Momii, Co-Founder and CEO
As the CEO of CellGevity, Scott oversees all aspects of business development and operations, which include domestic and international sales and marketing, manufacturing, patent management and licensing. Previous to CellGevity, he co-founded a prominent research, development and manufacturing company for specialty chemicals. His management responsibilities included overseeing and implementation of sales and marketing programs, domestic and international purchasing, as well as customer service and accounting. He spearheaded the development and launch of three products in the areas of cosmetics (which debuted in Japan), for the motion picture film industry, and a proprietary coating for high-speed ball bearings used in medical applications. He was responsible for transferring the manufacturing of a proprietary chemical to India. Simultaneously, he served as Director of Operations of a sister company, which develops biotechnology vaccines and cancer therapeutics, specializing in pharmaceutical delivery systems based on liposomal technology. Early in his career, he helped start a software company that developed a UNIX-based enterprise system designed for home infusion therapy and outpatient pharmacies. He was responsible for the sales of the software to over 200 hospitals, pharmacies and five national companies. He engineered the eventual sale of the company to the largest nationwide software provider for home healthcare solutions. Mr. Momii graduated with a B.A. degree from San Jose State University, received an M.B.A. from Boston University, and completed a summer business program at Jochi Daigaku (Sophia University), Tokyo, Japan.
Scott Nagasawa, Pharm.D. Co-Founder and Chief Technical Officer
Scott Nagasawa received his Doctor of Pharmacy degree from the University of Southern California (USC) and is a registered pharmacist. He spent over a dozen years at a 400-plus bed tertiary teaching hospital in Los Angeles, California, affiliated with the University of Southern California. At the time of his departure, he was the Director of Pharmaceutical Services. During this period, he held the position of Clinical Instructor of Pharmacy Practice at USC and was later promoted to Adjunct Assistant Professor of Pharmacy Practice. Scott transitioned into the business side of his profession and joined a regional pharmacy as their Vice President of Pharmacy Services. He was instrumental in the planning and implementation of a strategic business plan transforming the company from a regional to a nationwide pharmacy service provider with revenues exceeding $60 million annually. At the time of his departure, he held the position of Senior Vice President of Professional Services responsible for nursing and pharmacy operations. He left to become partner in a small home infusion service provider and helped develop and implement a business plan that resulted in rapid growth. The company was sold to a large pharmacy provider in California. He remained with the company as V.P. of Operations and at the time of his departure, the monthly revenue had grown by roughly 40 times. This revenue growth occurred over his four and a half year stay with the company. Scott then left to join CellGevity, and served full-time as the Chief Technical Officer (CTO). As CTO he is responsible for product registration, company certifications, regulatory practices, safety studies, technical sales support and the development and reviewing of product documentation.
